- Home
- NGNE vs LPRO Comparison
NGNE vs LPRO Comparison
Compare NGNE & LPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- LPRO
- Stock Information
- Founded
- NGNE 2003
- LPRO 2000
- Country
- NGNE United States
- LPRO United States
- Employees
- NGNE N/A
- LPRO N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- LPRO Finance: Consumer Services
- Sector
- NGNE Health Care
- LPRO Finance
- Exchange
- NGNE Nasdaq
- LPRO Nasdaq
- Market Cap
- NGNE 251.9M
- LPRO 245.6M
- IPO Year
- NGNE N/A
- LPRO N/A
- Fundamental
- Price
- NGNE $21.83
- LPRO $2.01
- Analyst Decision
- NGNE Buy
- LPRO Buy
- Analyst Count
- NGNE 6
- LPRO 7
- Target Price
- NGNE $39.83
- LPRO $3.44
- AVG Volume (30 Days)
- NGNE 224.0K
- LPRO 1.5M
- Earning Date
- NGNE 05-09-2025
- LPRO 05-07-2025
- Dividend Yield
- NGNE N/A
- LPRO N/A
- EPS Growth
- NGNE N/A
- LPRO N/A
- EPS
- NGNE N/A
- LPRO N/A
- Revenue
- NGNE $925,000.00
- LPRO $17,672,000.00
- Revenue This Year
- NGNE N/A
- LPRO $318.17
- Revenue Next Year
- NGNE N/A
- LPRO $6.66
- P/E Ratio
- NGNE N/A
- LPRO N/A
- Revenue Growth
- NGNE N/A
- LPRO N/A
- 52 Week Low
- NGNE $6.88
- LPRO $0.70
- 52 Week High
- NGNE $74.49
- LPRO $6.97
- Technical
- Relative Strength Index (RSI)
- NGNE 62.53
- LPRO 59.21
- Support Level
- NGNE $16.62
- LPRO $1.74
- Resistance Level
- NGNE $18.90
- LPRO $1.85
- Average True Range (ATR)
- NGNE 2.06
- LPRO 0.12
- MACD
- NGNE 0.38
- LPRO 0.01
- Stochastic Oscillator
- NGNE 60.81
- LPRO 65.12
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.